China’s National Healthcare Security Administration announced the latest centralized procurement plan of consumables, focusing on guiding IVD reagents procurement by provinces

Original from: SAIBAILAN

Carrying out new batches of national procurement, focusing on guiding the provincial procurement of in vitro diagnostic reagents

On 28 July, NHSA issued the "Notice on Providing Basic Medical Security for Urban and Rural Residents in 2023 by National Healthcare Security Administration, Ministry of Finance and State Taxation Administration" (hereinafter referred to as the "Notice").

The Notice points out that the coverage of centralized procurement of drugs and consumables will continue to be expanded, and new batches of nationally organized drugs and high-value medical consumables will be started, with a focus on guiding provinces to carry out the procurement of chemical medicines, proprietary Chinese medicines, as well as neurosurgical and in-vitro diagnostic reagents. 

In accordance with the "Notice of National Healthcare Security Administration Office on Pharmaceutical Centralized Procurement and Price Management in 2023", an inter-provincial alliance procurement of in vitro diagnostic reagents will be led by Anhui. 

The inter-provincial alliance and the provincial level of consumables procurement have been expanding, and some regions have tried to carry out one-time procurement of large quantities of consumables. 

For example, Hebei carried out a one-time procurement of 22 types of consumables last year and a one-time collection of 19 types of consumables this year, and some provinces and municipalities, such as Jiangxi, Qinghai, Anhui, Guangxi and others, have also joined the Hebei-led collection of consumables.

A research report pointed out that the current consumables procurement has been transformed from tens of billions of products to billions of products, and from mature, highly localized products to the bias of innovation and consuming products.